By Fineline Cube 
China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has formed a strategic partnership with Shaohe Biotechnology Co., Ltd. This collaboration aims to translate probiotic research from the laboratory to public health applications, offering precise and scientifically driven solutions for national health management.
Collaboration Objectives
The partnership focuses on advancing probiotic research and development. Shaohe Biotech will concentrate on strain research and optimization, utilizing its proprietary AI+BT high-efficiency screening platform and patented strain domestication technology. Lee’s Pharmaceutical will leverage its commercialization expertise and market experience to facilitate industry-academia-research collaboration and accelerate product development and market entry.
Health Management Solutions
By precisely regulating metabolic pathways and improving metabolic diseases, the collaboration seeks to provide more scientific and personalized solutions for national health management. This joint effort underscores the commitment of both companies to enhancing public health through innovative probiotic applications.-Fineline Info & Tech